Mezaxya

Amlodipine, the active ingredient in Mezaxya, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower high blood pressure and to relieve chest pain in patients with chronic stable angina. The medication works by relaxing the smooth muscle in blood vessel walls, which improves blood flow and reduces the workload on the heart.

GNH USA supplies Mezaxya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across all markets.

Mezaxya (amlodipine) is used in cardiovascular therapy to manage conditions related to high blood pressure and chest pain. Hypertension: Reduces systolic and diastolic blood pressure, helping to prevent complications such as stroke and heart failure. Chronic stable angina: Improves coronary blood flow, decreasing the frequency of angina attacks and enhancing exercise tolerance. Coronary artery disease (as part of combination therapy): Contributes to overall vascular protection and symptom control when used with other antihypertensive agents.

Amlodipine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet due to fluid accumulation. - Dizziness: light‑headed sensation, especially when standing quickly. - Fatigue: general feeling of tiredness. - Palpitations: awareness of heartbeat irregularities.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Liver enzyme elevation: significant increase in hepatic transaminases. - Allergic reactions: rash, itching, or swelling of the face and throat. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Heart block: abnormal cardiac conduction requiring medical attention.

Before initiating Mezaxya, clinicians should consider several safety measures to minimize risk. - Blood pressure monitoring: check baseline and periodic readings to assess response. - Cardiac assessment: evaluate for existing heart failure or conduction abnormalities. - Concomitant drug review: identify other antihypertensives or CYP3A4 inhibitors. - Hepatic impairment: use caution and consider dose adjustment in liver disease. - Abrupt discontinuation: avoid sudden stopping to prevent rebound hypertension. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Amlodipine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): increase amlodipine levels. - Simvastatin >20 mg: risk of myopathy due to higher statin concentrations. - Grapefruit juice: can raise drug exposure and cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may lower amlodipine effectiveness. - Beta‑blockers: additive heart rate reduction and hypotensive effect. - Diuretics: may enhance antihypertensive response, requiring blood pressure monitoring.